← Back to Clinical Trials
Recruiting NCT07093619

NCT07093619 Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Gradient Centrifugation in a PGT-A Program: a Sibling Oocyte Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07093619
Status Recruiting
Phase
Sponsor ART Fertility Clinics LLC
Condition Semen Analysis
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-09-12
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
FERTILE Plus

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2025-09-12 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In assisted reproductive technology (ART), sperm preparation aims to select the most viable sperm for ICSI. Unlike conventional methods like density gradients or sperm washing, microfluidic techniques mimic natural selection in the female reproductive tract by using laminar flow without centrifugation, reducing the risk of DNA damage. This method isolates highly motile sperm while filtering out debris and immotile cells. Studies show that microfluidics improve embryo quality, increase pregnancy rates, and may lead to higher euploidy rates. Additional benefits include improved safety, scalability, and shorter preparation times.

Eligibility Criteria

Inclusion Criteria: 1. Women with at least 8 MII per cycle after denudation (AFC≥8). 2. Women of all ages. 3. All embryo qualities ≥BL3CC at the time of biopsy on day 5, 6 and/or 7. 4. Fresh sperm used from ejaculate with a concentration ≥1 mill/ml and ≥10% motility (A+B). 5. Sperm samples with a minimum of 2 ml. Exclusion Criteria: * Frozen oocytes samples with severe oligospermia (≤1mill/ml). * PGT-M cases * Sperm with \> 1M/ml of round cells

Contact & Investigator

Central Contact

Jonalyn Edades, Research Coordinator

✉ jonalyn.edades@artfertilityclinics.com

📞 +97126528000

Principal Investigator

Barbara Lawrenz

STUDY DIRECTOR

ART Fertility Clinics LLC

Frequently Asked Questions

Who can join the NCT07093619 clinical trial?

This trial is open to participants of all sexes, studying Semen Analysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07093619 currently recruiting?

Yes, NCT07093619 is actively recruiting participants. Contact the research team at jonalyn.edades@artfertilityclinics.com for enrollment information.

Where is the NCT07093619 trial being conducted?

This trial is being conducted at Abu Dhabi, United Arab Emirates.

Who is sponsoring the NCT07093619 clinical trial?

NCT07093619 is sponsored by ART Fertility Clinics LLC. The principal investigator is Barbara Lawrenz at ART Fertility Clinics LLC. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology